August 2, 2012
Citing the "emergence of a serious safety issue," Bristol-Myers Squibb Co. said Wednesday it was voluntarily suspending the Phase II study of a hepatitis C drug candidate, BMS-986094. Earlier this year, BMS paid $2.5 billion to acquire Inhibitex Inc., the company that developed the nucleotide polymerase inhibitor formerly known as INX-189. "The cause of the safety issue and any potential relationship to the study drug are unknown at this time," BMS said in a statement. The company currently is assessing all the study patients and will decide on next steps following an evaluation of patient data.
Wall Street Journal
08.02.2012; Saabira Chaudhuri
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|The Company You Keep: Do Social Networks Influence HIV Status?|
|Incidence of All Cancers but Lung Cancer Drops After HIV Group Stops Smoking|
|New HIV Infections Drop 18% in 6 Years|
|HIV Vaccine Induces Sustained HIV Remission in Proof-of-Concept Study|
|Mental Health Complications of HIV Insufficiently Studied|
|HIV-Associated Neurocognitive Disorders and the Gut Microbiome|